Roger Deeley elected to Royal Society of Canada
Roger Deeley, President of the Kingston General Hospital Research Institute and Vice-Dean, Research, Queen’s Faculty of Health Sciences, has been named a Fellow of the Royal Society of Canada. Peer-selected fellowship in the Royal Society is one of the highest honours bestowed on Canadian scholars, artists and scientists in the arts, humanities, sciences and in Canadian public life.
The award reflects Dr. Deeley’s outstanding contributions to science, beginning with his pioneering work in molecular biology. His early investigations resulted in novel approaches to gene cloning, and laid the foundation for his subsequent breakthrough discovery, with Queen’s co-investigator Dr. Susan Cole, of the gene coding for a multidrug resistance protein (MRP). Their groundbreaking work represented a significant advancement in scientific understanding of why some patients developed resistance to drugs used to treat cancer and other diseases.
Author of approximately 190 papers and book chapters with more than 16,000 citations, Dr. Deeley is also a named inventor on 12 patents worldwide relating to this work, which continues to contribute significantly to drug development and cancer research. He has received numerous honours for his discoveries, including the Cancer Institute of Canada (NCIC) Diamond Jubilee Award (co-recipient), the NCIC Robert L. Noble Prize, and fellowship in the Canadian Academy of Health Sciences.
Dr. Deeley is a Professor of Pathology & Molecular Medicine, Stauffer Research Professor of Basic Oncology, and Director of the Queen’s Cancer Research Institute. Over the course of his research career, he has been involved in attracting more than $32 million in research funding.
Established in 1882, The Royal Society is Canada’s national academy for promoting learning and research in the arts, humanities and natural and social sciences.